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Abstract
Background: The 5-lipoxygenase enzyme is widely distributed within the central nervous system and its activity is
regulated by the presence and availability of another protein, called 5-lipoxygenase activating protein. While
previous works have shown that 5-lipoxygenase is involved in the pathogenesis of Alzheimer’s disease, no data are
available on the role that 5-lipoxygenase activating protein plays in Alzheimer’s disease.
Methods: In the present paper, we studied the effect of pharmacologic inhibition of 5-lipoxygenase activating
protein on the amyloidotic phenotype of Tg2576 mice.
Results: Amyloid β peptide (Aβ) deposition in the brains of mice receiving MK-591, a selective and specific 5-
lipoxygenase activating protein inhibitor, was significantly reduced when compared with controls. This reduction
was associated with a similar decrease in brain Aβ peptides levels. MK-591 treatment did not induce any change in
the steady-state levels of amyloid-β precursor protein, β-site amyloid precursor protein cleaving enzyme 1 or
disintegrin and metalloproteinase domain-containing protein 10. By contrast, it resulted in a significant reduction of
the γ-secretase complex, at the protein and message level. Furthermore, in vitro studies confirmed that MK-591
prevents Aβ formation by modulating γ-secretase complex levels without affecting Notch signaling.
Conclusions: These data establish a novel functional role for 5-lipoxygenase activating protein in the pathogenesis
of Alzheimer’s disease-like amyloidosis, and suggest that its pharmacological inhibition could provide a novel
therapeutic opportunity for Alzheimer’s disease.
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Background
The enzyme 5-lipoxygenase (5LO) catalyzes the conversion
of arachidonic acid to 5-hydroxyperoxyeicosatetraenoic
acid and subsequently to 5-hydroxyeicosatetraenoic acid,
which can be then metabolized into different leukotrienes
[1]. It is abundantly present in the central nervous system
(CNS), where its activity is regulated by the presence and
availability of another protein, 5LO-activating protein
(FLAP) [2]. From a biochemical point of view, they form
a functional complex whose integrity is necessary for the
full 5LO enzymatic activity. A peculiar aspect of the FLAP/
5LO pathway is the fact that its expression levels are
significantly increased in the CNS with aging, and that this
increase is also region-specific since it mainly manifests in
the hippocampus, an area vulnerable to neurodegenerative
insults [3].
Interestingly, recent studies showed that hippocampi
from patients with Alzheimer’s disease (AD) have higher
5LO immunoreactivity when compared with healthy
controls, and that the genetic absence of 5LO results in a
significant reduction of the brain amyloidotic phenotype
of amyloid-β precursor protein (APP) transgenic mice
(that is, Tg2576) [4,5]. Taken together, these data suggest
an involvement of this pathway in AD pathogenesis, and
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support the hypothesis that it plays a functional role in
AD development.
However, no studies are available testing the specific and
direct role that FLAP may also play in the development of
the AD-like amyloidotic phenotype of the Tg2576 mice.
To this end, in the current study we chronically admi-
nistered these mice with a selective and specific orally
available inhibitor of FLAP activation, MK-591 [6]. At
the end of the study, compared with mice receiving
vehicle, the group treated with MK-591 showed a signifi-
cant reduction in the amount of amyloid β peptide (Aβ)
formed and deposited in their brains. These changes
were not associated with any significant modification of
total APP, β-site amyloid precursor protein cleaving
enzyme 1 (BACE-1) or disintegrin and metalloproteinase
domain-containing protein 10 (ADAM-10) protein
levels. By contrast, we observed that the group adminis-
tered with MK-591 had a significant reduction of the
γ-secretase complex at the protein and message level.
These results were further confirmed in vitro using neur-
onal cells stably expressing the human APP Swedish mu-
tant, neuro-2 A neuroblastoma (N2A)-APPswe cells.
Methods
Mice and treatments
All animal procedures were approved by the Institutional
Animal Care and Usage Committee and in accordance with
the National Institute of Health guidelines. The Tg2576
transgenic mice expressing human APP with the Swedish
mutation (K670N/M671L) used in these studies were as
previously described [7]. They were genotyped by PCR
analysis using tail DNA and kept in a pathogen-free envir-
onment, on a 12-hour light/dark cycle and had access to
food and water ad libitum. All the experiments presented
in this paper were performed with female mice. Starting at
7 months of age, mice were randomized to receive MK-591
(40 mg/kg weight) (n = 11) or vehicle (n = 9) in their chow
diet for 8 months until they were 15 months old. Consider-
ing that each mouse eats on average 5 g/day of chow diet
and the diet is formulated for 320 mg MK-591 per kg diet
(Harlan Teklad, WI, USA), the final dose of the active drug
was approximately 40 mg/kg weight/day. During the study,
mice in both groups gained weight regularly, and no signifi-
cant difference in weight was detected between the two
groups. No macroscopic effect on the overall general health
was observed in the animals receiving the active treatment.
Post-mortem examination showed no sign of macroscopic
pathology in any of the organs considered (spleen, liver, thy-
mus, ileum).
After sacrifice, animals were perfused with ice-cold
0.9% PBS, the brain removed and dissected in two by mid-
sagittal dissection. One was immediately stored at −80°C
for biochemistry assays or total RNA extraction, and the
other immediately immersed in 4% paraformaldehyde
in 0.1 M PBS (pH 7.6) overnight for immunohistochemis-
try studies.
Immunohistochemistry
Immunostaining was performed as reported previously
by our group [8,9]. Serial 6-μm-thick coronal sections
were mounted on 3-aminopropyltriethoxysilane-coated
slides. Every eighth section from the habenular to the
posterior commissure (8 to 10 sections per animal) was
examined using unbiased stereological principles. The
sections for Aβ were deparaffinized, hydrated, pretreated
with formic acid (FA; 88%) and subsequently with 3%
hydrogen peroxide in methanol. The sections for glial
acidic fibrillary protein (GFAP) and CD45 were deparaf-
finized, hydrated and treated with 3% hydrogen peroxide
in methanol and subsequently antigen retrieved with cit-
rate (10 mM). Sections were blocked in 2% fetal bovine
serum before incubation with primary antibodies (4 G8
for Aβ, anti-GFAP, and anti-CD45) overnight at 4°C.
Subsequently, sections were incubated with biotinylated
anti-mouse IgG (Vector Laboratories, Burlingame, CA,
USA) and then developed using the avidin-biotin
complex method (Vector Laboratories) with 3,3’-diami-
nobenzidine as a chromogen. Light microscopic images
were used to calculate the area occupied by Aβ-
immunoreactivity using the software Image-Pro Plus for
Windows version 5.0 (Media Cybernetics, Bethesda,
MD, USA). The threshold optical density that discrimi-
nated staining from background was determined and
kept constant for all quantifications. The area occupied
by Aβ-immunoreactivity was measured by the software
and divided by the total area of interest to obtain the
percentage area of Aβ-immunoreactivity.
Biochemical analyses
Mouse brain homogenates were sequentially extracted
first in radioimmunoprecipitation assay (RIPA) for the
Aβ soluble fractions and then in FA for the Aβ insoluble
fractions as previously described [5,8,9]. Aβ1-40 and
Aβ1-42 levels were assayed by a sensitive sandwich
ELISA kits (WAKO Chem, Richmond, VA, USA.). Inter-
leukin 1-β (IL-1β) levels in brain homogenates were
assayed by a specific and sensitive sandwich ELISA kit,
following the manufacturer’s instructions (R&D Systems,
Minneapolis, MN, USA). Supernatants from the cell cul-
ture experiments were also assayed for their levels of
lactate dehydrogenase (LDH) by a colorimetric assay kit
(BioVision, Milpitas, CA, USA). Analyses were always
performed in duplicate and in a coded fashion.
Western blot analyses
RIPA extracts from brain homogenates were used for
western blot analyses. Samples were electrophoresed on
10% Bis-Tris gels or 3% to 8% Tris-acetate gel (Bio-Rad,
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Richmond, CA, USA), according to the molecular weight
of the target molecule, transferred onto nitrocellulose
membranes (Bio-Rad), and then incubated with appropri-
ate primary antibodies as follows: anti-APP N-terminal
raised against amino acids 66 to 81 for total APP (22 C11,
Chemicon International, Temecula, CA, USA), anti-
BACE-1 (IBL America, Minneapolis, MN,USA), anti-
ADAM-10 (Chemicon), anti-secreted-APPα (2B3, IBL
America), anti-secreted-APPβ (6A1, IBL America), anti-
C-terminal fragments (CTF; EMD Biosciences, Inc.,
Billerica, MA, USA), anti-presenilin1 (PS1; Sigma, St. Lousi,
MO,USA), anti-nicastrin (Cell Signaling, Daners, MA,
USA), anti-anterior pharynx-defective 1 (APH-1; Millipore,
Billerica, MA, USA), anti-presenilin enhancer 2 (Pen-2;
Invitrogen, Grand Island, NY, USA), anti-GFAP (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-5LO (BD
Transduction Laboratories, San Jose, CA, USA); anti-Notch
intracellular domain (NICD; Cell Signaling), anti-insulin-
degrading enzyme (IDE) N-terminal (EMD Biosciences),
anti-neprilysin (Santa Cruz Biotechnology, Inc.), anti-
apolipoprotein E (Santa Cruz Biotechnology, Inc.), anti-
cAMP response element-binding protein (CREB; Cell
Signaling) and anti-phosphorylated-CREB (Cell Signaling),
anti-Sp1 (Santa Cruz Biotechnology, Inc.) and anti-β actin
(Santa Cruz Biotechnology, Inc.).
After three washings with T-TBS (Tween-Tris Buffered
Saline), membranes were incubated with IRDye 800CW
or IRDye 680CW-labeled secondary antibodies (LI-COR
Bioscience, Lincoln, NE, USA) at 22°C for 1 h. Signals
were developed with Odyssey Infrared Imaging Systems
(LI-COR Bioscience). β-actin was always used as internal
loading control.
Real-time quantitative RT-PCR amplification
RNA was extracted and purified using the RNeasy mini-
kit (Qiagen, Valencia, CA, USA), as previously described
[10]. Briefly, 1 μg of total RNA was used to synthesize
cDNA in a 20 μL reaction using the RT² First Strand Kit
RT-PCR (Super Array Bioscience, Valencia, CA, USA).
Mouse BACE-1, PS1, nicastrin, APH-1 and Pen-2 genes
were amplified by using the corresponding primers
designed and synthesized by Super Array Bioscience. β-
actin was always used as an internal control gene to
normalize for the amount of RNA. Real-time PCR was
performed in an Eppendorf ep realplex thermal cycler
(Eppendorf, Hauppauge, NY, USA). Two microliters
of cDNA was added to 25 μL of SYBR Green PCR
Master Mix (Applied Biosystems, Carlsbad, CA, USA).
Each sample was run in duplicate, and analysis of
relative gene expression was done by using the 2-ΔΔCt
method [11]. Briefly, the relative change in gene ex-
pression was calculated by subtracting the threshold
cycle (ΔCt) of the target genes from the internal
control gene (β-Actin). Based on the fact that the
amount of cDNA doubles in each PCR cycle (assum-
ing a PCR efficiency of 100%), the final fold-change
in gene expression was calculated by using the for-
mula relative change = 2-ΔΔCt [11].
Cell cultures
N2A cells stably expressing human APP carrying the
K670N/M671L Swedish mutation (APPswe) were grown
in Dulbecco’s modified Eagle medium supplemented
with 10% fetal bovine serum, 100 U/mL penicillin, 100
μg/mL streptomycin (Cellgro, Herdon, VA, USA), and
400 μg/mL G418 (Invitrogen), at 37°C in the presence of
5% CO2 as previously described [10].
For each experiment, equal numbers of cells were pla-
ted in six-well plates; 24 h later media were removed
and fresh media containing either MK-591 (1 μM, 10
μM or 25 μM) or vehicle were added. After incubation
for 24 h, supernatants were collected for Aβ and LDH
measurement, and cell pellets harvested in lytic buffer
for immunoblot analyses as described in the previous
paragraphs.
For transfection studies, N2A-APPswe cells were
transfected with 1 μg Myc-tagged mΔE-Notch-1 com-
plementary DNA overnight (a generous gift from Dr. L.
D´Adamio, Albert Einstein Medical College, NY, USA)
by using Lipofectamine 2000 (Invitrogen). The media
were removed and fresh media containing MK-591,
L685,458 or vehicle were added. After incubation for 24
h, cells lysates were collected NICD expression levels
assayed by western blot analysis.
Data analysis
Data analyses were performed using SigmaStat for
Windows version 3.00. Statistical comparisons were
performed by unpaired Student’s t-test or the Mann–
Whitney rank sum test when a normal distribution could
not be assumed. Values represent mean ± standard error
of the mean. Significance was set at P <0.05.
Results
In vivo studies
5-lipoxygenase activating protein blockade reduces brain
Aβ peptides levels and deposition
Starting at 7 months of age, Tg2576 mice were rando-
mized to receive MK-591 (320 mg/kg diet) or vehicle in
their chow diet for 8 months before being killed. Consid-
ering that each mouse eats on average 5 g/day of chow
diet, the final dose of the active drug was approximately
40 mg/kg weight/day. By the end of the study, body
weight, total plasma cholesterol, triglycerides and blood
cell counts were not different between the two groups
(not shown).
As expected for their age, 15-month-old Tg2576 mice
on vehicle showed elevated levels of both soluble (RIPA
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extractable) and insoluble (FA extractable) Aβ1-40 and
Aβ1-42 in their cerebral cortex as well as hippocampus,
the levels of which were significantly reduced in mice re-
ceiving MK-591 (Figure 1A-D).
Amyloid deposits were widely distributed in the cere-
bral cortex and hippocampus of Tg2576 mice at 15
months of age, as previously reported [12]. To determine
the effect of chronic MK-591 administration on brain
amyloid deposition, the areas occupied by 4 G8-
immunopositive reactions were analyzed. Comparison of
the Aβ-immunopositive areas between the placebo and
MK-591-treated group revealed a statistically significant
reduction of the amyloid burden in the treated mice
(Figure 1E, F).
5-lipoxygenase activating protein blockade influences brain
amyloid-β precursor protein metabolism
Since Aβ is the final product of the proteolytic pro-
cessing of its own precursor, APP, next we investi-
gated whether this pharmacologic treatment was
associated with an alteration on the expression levels
of this protein. As shown in Figure 2A, we found that
there was no difference in total APP levels between
the two groups of mice. To assess the effect of MK-
591 on APP processing, we investigated the steady-
state levels of the main enzyme proteases involved,
α-secretase (ADAM-10), β-secretase (BACE-1) and
the four components of the γ-secretase complex, by
western blot analysis. As shown in Figure 2A, B, no
significant differences in the levels of ADAM-10,
BACE-1, secreted APPα, secreted APPβ or CTFs were
observed between the two groups of mice. By con-
trast, we observed that mice receiving MK-591 had a
statistically significant reduction in the steady-state
levels of three of the four components of the γ-
secretase complex, PS1, Pen-2 and APH-1 (Figure 2A,
B). Despite an observed reduction for nicastrin, it did
not reach statistical significance (p = 0.06). Further-
more, quantitative real-time RT-PCR analyses revealed
that, in the same mice, the mRNA levels of these
four proteins were significantly reduced (Figure 2C).
By contrast, no change was observed in the BACE-1
mRNA levels (Figure 2C).
5-lipoxygenase activating protein blockade does not affect
Aβ catabolic pathways
Since the final amount of Aβ assayed is the result of
production and degradation, next we analyzed two of
the major proteases involved in its catabolism: IDE
and neprilysin [13]. Steady-state levels of both pro-
teins measured by western blot analysis were similar
between the two groups of mice (not shown). A
similar result was observed when we measured levels
of the apolipoprotein E, which has been implicated
in the clearance of Aβ from the CNS by acting as
chaperone [14] (not shown).
Figure 1 Pharmacologic blockade of 5-lipoxygenase activating protein decreases brain Aβ peptides levels and deposition. (A-D) RIPA-
soluble (RIPA) and formic acid extractable (FA) Aβ1-40 and Aβ1-42 levels in cortex and hippocampus of Tg2576 receiving MK-591 or placebo for
8 months were measured by sandwich ELISA. (n = 9 for control, and n = 11 for MK-591; *P <0.04). (E) Representative sections of brains from
Tg2576 mice receiving MK-591 or placebo (control) for 8 months immunostained with 4 G8 antibody. (F) Quantification of the area occupied by
Aβ immunoreactivity in brain of Tg2576 mice receiving MK-591 or placebo for 8 months (*P = 0.03). ELISA: enzyme-linked immunosorbent assay;
FA: formic acid; RIPA: radioimmunoprecipitation assay.
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5-lipoxygenase activating protein blockade modulates
neuroinflammation
Since neuroinflammation is also an important feature of
this AD-like amyloidosis model [15], next we investi-
gated the effect of FLAP pharmacologic blockade on
microglia and astrocytes activation. As shown in
Figure 3A-D, mice receiving MK-591 had a significant
decrease in the immunoreactivity for CD45, a marker of
microgliosis, and GFAP, a marker of astrogliosis. Immu-
noblot analysis confirmed the significant reduction of
GFAP in brain homogenates from mice receiving MK-
591, which was accompanied by a significant reduction
in the steady-state levels of 5-LO (Figure 3E, F). Finally,
we observed that animal receiving MK-591 also had a
significant reduction in brain levels of IL-1β (Figure 3G).
MK-591 affects cAMP response element-binding protein but
not Sp1
The data collected so far suggest that MK-591 by block-
ing FLAP regulates the γ-secretase complex expression
at the transcriptional level. Since previous studies have
shown that 5LO activation by producing hydroxy-
eicosatetraenoic acids can influence CREB, a transcrip-
tional factor that regulates gene expression [10], we
wanted to test if this was also the case in our system.
Compared with mice on placebo, we found that mice
treated with MK-591 showed a statistically significant
decrease in the steady-state levels of total CREB and its
phosphorylated form at Ser133. However, MK-591 did
not significantly affect the steady-state levels of Sp1, an-
other transcription factor (Figure 2D, E).
Figure 2 Pharmacologic blockade of 5-lipoxygenase activating protein alters amyloid-β precursor protein metabolism via the
γ-secretase pathway. (A) Representative western blots of APP, ADAM-10, BACE-1, secreted APPα, secreted APPβ, CTFs, PS1, nicastrin, APH-1 and
Pen-2 in brain homogenates of Tg2576 mice receiving MK-591 or placebo for 8 months. (B) Densitometric analysis of some of the
immunoreactivities to the antibodies shown in the previous panel (n = 9 control, n = 11 MK-591; *P <0.04). (C) Relative mRNA levels for BACE-1,
PS1, nicastrin, APH-1 and Pen-2 in brain homogenates of Tg2576 mice receiving MK-591 or placebo for 8 months, as determined by real-time
quantitative RT-PCR amplification (*P <0.02). (D) Representative western blot for total cAMP response element-binding and its phosphorylated
form at Ser133, and Sp1 in brain homogenates of Tg2576 mice receiving MK-591 or placebo. (E) Densitometric analysis of the immunoreactivities
to the antibodies shown in the previous panel (n = 9 control, n = 11 MK-591; *P <0.03). ADAM-10: disintegrin and metalloproteinase domain-
containing protein 10; APH-1: anterior pharynx-defective 1; APP: amyloid-β precursor protein; BACE-1: β-site amyloid precursor protein cleaving
enzyme 1; CREB: cAMP response element-binding protein; CTF: C-terminal fragments; Pen-2: presenilin enhancer 2; PS1: presenilin1; RT-PCR:
reverse transcriptase polymerase chain reaction.
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In vitro studies
MK-591 influences Aβ formation in a γ-secretase-dependent
manner
To further confirm our ex vivo observation, we embarked
in a series of in vitro experiments. N2A-APPswe cells were
incubated with MK-591 for 24 hours at different concentra-
tion (1 μM, 10 μM and 25 μM) or vehicle. At the end of
this period, conditioned media showed that, compared with
control (0.327 ± 0.003), the presence of MK-591 did not
alter the levels of LDH (1 μM, 0.347 ± 0.01; 10 μM, 0.331 ±
0.01; 25 μM, 0.346 ± 0.006; absorbance 450 nm). The same
drug reduced Aβ1-40 formed by these cells in a dose-
dependent manner (Figure 4A). This reduction was asso-
ciated with a significant decrease in the steady-state levels
of PS1, nicastrin, APH-1 and Pen-2 proteins, the four com-
ponents of the γ-secretase complex (Figure 4B, C). By con-
trast, MK-591 did not influence the protein levels for APP,
BACE-1 or ADAM-10 (Figure 4B, C).
MK-591 influences cAMP response element-binding protein
but not Sp1
Similar to the in vivo experiments, we also observed that
incubation of MK-591 with N2A-APP cells resulted in a
significant decrease in the expression levels of CREB and
Figure 3 Pharmacologic blockade of 5-lipoxygenase activating protein reduces neuroinflammation. (A, C) Representative brain sections
of the cortex region from Tg2576 receiving MK-591 or vehicle (control) immunostained for CD45 and GFAP (× 20 magnification). (B, D)
Quantitative analysis of the immunoreactivity for CD45 and GFAP in the same animals. (E) Representative western blot analysis of GFAP and 5-LO
in brain homogenates of Tg2576 receiving MK-591 or control. (F) Densitometric analysis of the immunoreactivities to the antibodies shown in the
previous panel. (G) Levels of IL-1β in brain homogenates of Tg2576 mice receiving MK-591 or controls (n = 8 controls, n = 10 MK-591;*P = 0.01).
CD45: cluster of differentiation 45; GFAP: glial acidic fibrillary protein; 5-LO: 5-lipoxygenase.
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p-CREB. By contrast, the presence of the drug did not
induce any significant alteration in the levels of the tran-
scription factor Sp1 (Figure 5A, B).
MK-591 does not affect Notch signaling
Since Notch is another possible substrate for γ-secretase
proteolytic activity, we tested whether this pathway was
Figure 4 (See legend on next page.)
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affected by the treatment. To this end, we assessed the
effect of MK-591 on γ-secretase-mediated cleavages of
Notch. N2A-APPswe cells were transfected with Myc-
tagged mΔE-Notch-1 cDNA and incubated with MK-591
at the same concentrations which reduced γ-secretase
components. We then assessed the expression levels of
NICD by western blot analysis. As shown in Figure 5C, D
no significant difference in the levels of NICD was
observed between cells with and without MK-591 treat-
ment. By contrast, when the specific γ-secretase inhibitor
Figure 5 In vitro effect of MK-591 on cAMP response element-binding protein and Notch. N2A-APPswe cells were incubated with
increasing concentration of MK-591 or vehicle for 24 hours, and cell lysates collected for immunoassays. (A) Representative western blots of total
CREB, its phosphorylated form (p-CREB) at Ser133, and Sp1 levels. (B) Densitometric analyses of the immunoreactivities to the antibodies to CREB,
p-CREB and Sp1 (*P <0.01). (C) Representative western blots of NICD in the lysates of cells treated with MK-591, L685,458 or vehicle groups. (D)
Densitometric analyses of the immunoreactivities to the antibodies NICD (n = 4; *P <0.01). CREB: cAMP response element-binding protein; NICD:
Notch intracellular domain; N2A-APPswe: neuro-2 A neuroblastoma cells expressing human APP carrying the K670N/M671L Swedish mutation.
(See figure on previous page.)
Figure 4 In vitro effect of MK-591 on Aβ formation and amyloid-β precursor protein metabolism. N2A-APPswe cells were incubated with
increasing concentration of MK-591 or vehicle for 24 h, and conditioned media and cell lysates collected. (A) Aβ1-40 levels in the supernatant
assayed by sandwich ELISA (n = 4 per each condition; *P <0.01). (B) Representative western blots of APP, ADAM-10, BACE-1, PS1, nicastrin, APH-1,
and Pen-2 in the lysates of MK-591 or vehicle-treated cells. (C) Densitometric analyses of the immunoreactivities to the antibodies shown in panel
B (*P <0.01). ADAM-10: disintegrin and metalloproteinase domain-containing protein 10; APH-1: anterior pharynx-defective 1; APP: amyloid-β
precursor protein; BACE-1: β-site amyloid precursor protein cleaving enzyme 1; ELISA: enzyme-linked immunosorbent assay; N2A-APPswe: neuro-2
A neuroblastoma cells expressing human APP carrying the K670N/M671L Swedish mutation; Pen-2: presenilin enhancer 2; PS1: presenilin1.
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L685,458 was used, a significant reduction in NICD
levels was detected (Figure 5C, D).
Discussion
The data presented in this study demonstrate that
pharmacologic blockade of FLAP significantly reduces
brain Aβ formation and deposition in the Tg2576 mouse
model of AD, and thereby provide the first evidence that
this protein is a novel therapeutic target for modulating
amyloidogenesis in vivo.
FLAP is an integral membrane protein of 18 kDa with
the known function of activating the 5LO enzyme by
directly associating and presenting it with its natural
substrate, arachidonic acid, for the formation of potent
biologically active lipids such as leukotrienes [16,17].
From a biochemical point of view, FLAP and 5LO form
a functional complex whose integrity is necessary for the
full enzymatic activation of this pathway [18].
Interestingly, in recent years a lot of work has been fo-
cused on the enzyme 5LO and its relationship with brain
aging and AD-like amyloidosis. Thus, the 5LO protein is
up-regulated in the CNS with aging, and its genetic defi-
ciency or pharmacologic blockade significantly reduced
brain amyloidosis in Tg2576 mice, suggesting a func-
tional role for it in modulating Aβ levels and deposition
[3,5,19]. However, so far no data are available on the
specific and direct role that FLAP may have in vivo in
the same transgenic mouse model.
With the present study, we wanted to test the hypoth-
esis that the FLAP protein, alongside 5LO, is a potential
target for modulating in vivo the AD-like brain amyloi-
dotic phenotype of Tg2576 mice.
MK-591 is an orally available selective and specific
FLAP inhibitor whose binding site partially overlaps with
the arachidonic acid binding site, making it impossible
for this substrate to be oxygenated by 5-LO [20]. We
demonstrated that use of this inhibitor is associated with
a significant reduction in brain amyloidosis in Tg2576
mice. In an effort to elucidate the mechanisms respon-
sible for the Aβ reduction in the mice receiving MK-591,
we assessed the steady state levels of APP and the levels
of the three most important proteases involved in its
processing, α-, β- and γ-secretase, which ultimately re-
sult in the formation of Aβ peptides. We found that total
APP, BACE-1 (β-secretase) and ADAM-10 (α-secretase)
protein levels were unaltered by the drug, suggesting
that the in vivo biological effects of MK-591 are not
mediated by modulation of the Aβ precursor or the α-
or β-cleavage proteolytic pathways. By contrast, we
observed that the γ-secretase complex was significantly
reduced by this treatment, supporting the hypothesis
that this pathway is specifically influenced by the active
treatment. Interestingly, in association with a reduction
in the steady-state levels of its proteins, we observed that
their mRNAs were significantly decreased. This suggests
translational regulation of the genes codifying for the γ-
secretase complex.
Different potential transcriptional factor binding sites
have been reported within the promoter regions of these
genes. Among them, a CREB binding site has been
shown to be essential for APH-1, Pen-2 and PS1 tran-
scriptional regulation [21,22]. In our studies we found
that, compared with the vehicle group, mice receiving
MK-591 had a significant reduction in the levels of this
transcription factor. By contrast, no difference between
the two groups was observed when levels of Sp1, a tran-
scription factor known to be involved in the regulation
of the β-secretase-1 mRNA [23], were assayed, suggest-
ing a specific effect on CREB.
Taken together, these findings support the hypothesis
that FLAP pharmacological blockade by preventing 5LO
activation modulates CREB levels and results in reduced
transcription of the mRNAs for the γ-secretase complex,
which ultimately is responsible for the reduction in Aβ
formation in vivo.
Aβ is a major component of the hallmark AD brain
lesions, and is generated from the sequential proteolytic
processing of APP by the enzymes β- and γ-secretase
[24]. The necessary role of γ-secretase in the pathogen-
esis of AD makes it a major target for drug development,
with an effort focused on the ability to inhibit this com-
plex. However, a key factor in establishing the clinical
validity of γ-secretase inhibitors is the demonstration of
a differential effect between APP processing and alterna-
tive substrates of this secretase, particularly the Notch
signaling. Here, we demonstrate that the MK-591 effect
on the γ-secretase complex is completely independent of
any effect on the Notch signaling pathway. This in vitro
observation is further supported by the fact that, during
the study and at the end of the chronic treatment,
animals receiving the active drug did not have any
macroscopic difference in organs that are typical Notch
targets.
The novel biological effect of the drug used in the
current study is in agreement with previous studies and
in line with a modulator activity of this drug on the
secretase. It supports the novel idea that it is possible to
develop γ-secretase modulators that alter Aβ formation
while preserving other important functions of the com-
plex [25]. This observation makes any potential thera-
peutic application of FLAP inhibitor(s), which could act
as γ-secretase modulators, in AD feasible without the
potential toxicity of the classical inhibitors of the com-
plex [26,27].
Conclusions
Our studies establish FLAP as a novel therapeutic target
for AD-like amyloidosis. They represent the successful
Chu and Praticò Journal of Neuroinflammation 2012, 9:127 Page 9 of 10
http://www.jneuroinflammation.com/content/9/1/127
completion of the initial step for pre-clinical development
of inhibitors of this protein as potential novel disease-
modifying agents for AD.
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